FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

Cigna’s Express Scripts called the report “another set of misleading conclusions based on a subset of medications that represent less than 2% of what our health plans spend on medications in a year” ...

The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...

The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...